局部晚期宫颈癌中β-微管蛋白Ⅲ的表达及意义

The expression and clinical significance of β tubulin Ⅲ in locally advanced cervical cancer

目的探讨β-微管蛋白Ⅲ在局部晚期宫颈癌（LACC）组织中的表达及其意义。方法应用免疫组织化学SP法检测47例LACC组织中β-微管蛋白Ⅲ的表达情况，分析β-微管蛋白Ⅲ的表达与紫杉醇新辅助化疗（NACT）的疗效及临床病理参数的关系。结果47例LACC中，NACT有效率为72．3％（34／47）。β-微管蛋白Ⅲ阳性表达率为72．3％（34／47），其中表达（＋）者占40．4％（19／47），（＋＋）者占12．8％（6／47），（＋＋＋）者占19．1％（9／47）。β-微管蛋白Ⅲ高表达患者NACT有效率为46．7％（7／15），低表达患者为84．4％（27，32），两者比较差异有统计学意义（P=0．007）。β-微管蛋白Ⅲ在LACC组织的表达与病理分级呈显著性相关（P=0．021），与病理类型、临床分期及淋巴结转移无显著性相关（P=0．822、0．336、0．839）。结论紫杉醇联合铂类行NACT对LACC有效，LACC组织中β-微管蛋白Ⅲ异常表达与紫杉醇耐药有关，与宫颈癌的生物学行为有关，可能是宫颈癌预后判断的一项生物学指标。

Objective To investigate the expression and clinical significance of β tubulin Ⅲ in locally advanced cervical cancer （LACC）. Methods The expression of β tubulin Ⅲ in tumor tissue of 47 patients with LACC was detected by immunohistochemical SP method. The relationship between expression of β tubulin Ⅲ and neoadjuvant chemotherapy （NACT） with paclitaxel,clinical data were analyzed retrospectively. Results The response rate of NACT was 72.3% （34/47）. The β tubulin Ⅲ positive expression rate was 72.3%（34/47 ）, （＋） expression rate was 40.4%（ 19/47 ）, （＋＋） expression rate was 12.8% （6/47）, （＋＋＋） expression rate was 19.1%（9/47）. The response rate of NACT in patients with （＋＋） and （＋＋＋） expression was significantly lower than that in patients with （-） and （＋） expression [46.7%（7/15） vs. 84.4% （27/32）,P = 0.007]. The expression of β tubulin Ⅲ was related to pathological grade （P = 0.021）,it was not related to pathological type,clinical stage,status of lymph node metastasis （P = 0.822,0.336,0.839）. Conclusions The NACT of paelitaxel combined with cisplatin is effective to LACC. The abnormality expression of β tubulin Ⅲ in LACC tissue relates to drug resistance of paclitaxel and biological behavior of cervical cancer, it may be an index to predict prognosis of cervical cancer.